Assessment of metabolic changes in the striatum of a rat model of parkinsonism: An in vivo 1H MRS study

NMR in Biomedicine

Volumn 22, Issue 2, 2009, Pages 207-212

  Kickler, Nils ^a,b,e   Lacombe, E ^a,b   Chassain, C ^c   Durif, F ^c   Krainik, A ^a,b,d   Farion, R ^a,b   Provent, P ^a,b   Segebarth, C ^a,b   Remy C ^a,b   Savasta, M ^a,b  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b UNIV GRENOBLE ALPES   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e EPFL   (Switzerland)

Author keywords

6 OHDA rat model; Glutamate; Parkinson's disease; Proton MRS

Indexed keywords

AMINO ACIDS; METABOLISM; NEURONS; RATS;

DOPAMINERGIC NEURONS; GAMMA-AMINOBUTYRIC ACIDS; GLUTAMATE; L-3 ,4-DIHYDROXYPHENYLALANINE; METABOLIC CHANGES; PARKINSON'S DISEASE; PROTON MRS; RAT MODEL;

NEURODEGENERATIVE DISEASES;

4 AMINOBUTYRIC ACID; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; LACTIC ACID; LEVODOPA; N ACETYLASPARTIC ACID; OXIDOPAMINE; DIAGNOSTIC AGENT; PROTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN METABOLISM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IN VIVO STUDY; LEFT HEMISPHERE; MALE; METABOLITE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RIGHT HEMISPHERE; SIGNAL NOISE RATIO; STRIATONIGRAL DEGENERATION; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PARKINSON DISEASE; PROTONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 64549141657     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1305     Document Type: Article

References (31)

1. Graybiel AM, Hirsch EC, Agid Y. The nigrostriatal system in Parkinson's disease. Adv. Neurol. 1990; 53: 17-29.
2. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990; 13(7): 272-276.
3. Schmidt WJ, Bubser M, Hauber W. Excitatory amino acids and Parkinson's disease. Trends Neurosci. 1990; 13(2): 46-47.
4. Jonkers N, Sarre S, Ebinger G, Michotte Y. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 2002; 926(1-2): 149-155.
5. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999; 88(1): 1-16.
6. Bruet N, Windels F, Carcenac C, Feuerstein C, Bertrand A, Poupard A, Savasta M. Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats. J. Neuropathol Exp. Neurol. 2003; 62(12): 1228-1240.
7. Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol Biol. Psychiatry 2002; 26(1): 127-138.
8. Chassain C, Bielicki G, Donnat JP, Renou JP, Eschalier A, Durif F. Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat. Exp. Neurol. 2005; 191(2): 276-284.
9. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: New York, 1986.
10. Chritin M, Feuerstein C, Savasta M. Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat. Brain Res. Mol. Brain Res. 1993; 19(4): 318-322.
11. Rodriguez M, Morales I, Gonzalez-Mora JL, Gomez I, Sabate M, Dopico JG, Rodriguez-Oroz MC, Obeso JA. Different levodopa actions on the extracellular dopamine pools in the rat striatum. Synapse 2007; 61(2): 61-71.
12. Wachtel SR, Abercrombie ED. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopaminetreated rats: differential effects of monoamine oxidase A and B inhibitors. J. Neurochem 1994; 63(1): 108-117.
13. Gruetter R, Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn. Reson Med. 1993; 29(6): 804-811.
14. 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn. Reson. Med. 1999; 41(4): 649-656.
15. Provent P, Kickler N, Barbier EL, Bergerot A, Farion R, Goury S, Marcaggi P, Segebarth C, Coles JA. The ammonium-induced increase in rat brain lactate concentration is rapid and reversible and is compatible with trafficking and signaling roles for ammonium. J. Cereb Blood Flow Metab. 2007; 27(11): 1830-1840.
16. 31P nuclear magnetic resonance. J. Neurochem 1989; 52(3): 741-749.
17. Remy C, Arus C, Ziegler A, Lai ES, Moreno A, Le Fur Y, Decorps M. In vivo, ex vivo, and in vitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intracerebral glioma in rat brain: assignment of resonances. J. Neurochem 1994; 62(1): 166-179.
18. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13(3): 129-153.
19. Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur. J. Neurol. 2001; 8(6): 573-577.
20. Fillenz M. In vivo neurochemical monitoring and the study of behaviour. Neurosci. Biobehav. Rev. 2005; 29(6): 949-962.
21. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2004; 20(5): 1255-1266.
22. Galeffi F, Bianchi L, Bolam JP, Della Corte L. The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci. 2003; 18(4): 856-868.
23. Corsi C, Pinna A, Gianfriddo M, Melani A, Morelli M, Pedata F. Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur. J. Pharmacol. 2003; 464(1): 33-38.
24. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur. J. Neurol. 2000; 7(6): 661-665.
25. Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat. Med. 1998; 4(11): 1308-1312.
26. Cruz CJ, Aminoff MJ, Meyerhoff DJ, Graham SH, Weiner MW. Proton MR spectroscopic imaging of the striatum in Parkinson's disease. Magn. Reson Imaging 1997; 15(6): 619-624.
27. Ellis CM, Lemmens G, Williams SC, Simmons A, Dawson J, Leigh PN, Chaudhuri KR. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997; 49(2): 438-444.
28. Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Patronas NJ, Hallett M. Proton magnetic resonance spectroscopic imaging in progressive supranuclear pałsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120(Pt 9): 1541-1552.
29. 1H nuclear magnetic resonance spectroscopy: noninvasive neurochemistry for basic research and clinical applications. Current topics in Neurochemistry 1997; 1: 59-85.
30. Podell M, Hadjiconstantinou M, Smith MA, Neff NH. Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. Exp. Neurol. 2003; 179(2): 159-166.
31. Demougeot C, Marie C, Giroud M, Beley A. N-Acetylaspartate: a literature review of animal research on brain ischaemia. J. Neurochem. 2004; 90: 776-783.